Nouscom

Geneos Therapeutics

This company develops personalised DNA-based therapeutic cancer vaccines and immunotherapies for patients with advanced hepatocellular carcinoma and other solid tumours.

Neogene Therapeutics

This biotechnology company develops engineered T cell receptor therapies targeting neoantigens in solid cancers for patients with oncology needs.

NeoPhore

This company develops small-molecule immuno-oncology medicines that inhibit DNA mismatch repair to stimulate immune responses against cancer for patients with solid tumours.

Neobe

The company develops engineered microbial biotherapeutics designed to disrupt the microenvironment of solid tumours for cancer patients receiving immunotherapy.

PanCancerT

This biotech company develops T-cell receptor therapies for patients with solid tumours, focusing on targets like triple-negative breast cancer and melanoma.

Hubro Therapeutics

This company develops neoantigen-targeted cancer vaccines for patients with gastrointestinal cancers to activate anti-cancer specific T-cell immune responses.

Enara Bio

This company develops cancer immunotherapies targeting antigens derived from the dark genome for patients with solid tumours.

Akamis Bio

This clinical-stage oncology company develops intravenously administered immunotherapies to treat solid tumours, specifically targeting patients living with colorectal cancer.